Kyverna Therapeutics Appoints Greg Martini as CFO

Kyverna Therapeutics has appointed Greg Martini as its Chief Financial Officer in preparation for a potential commercial launch of its autoimmune disease cell therapy candidate, miv-cel. Martini previously worked at Ironwood Pharmaceuticals.

By Pratyush Thakur, SA News Editor · Seeking Alpha · May 18, 2026, 12:16 UTC

Kyverna Therapeutics Appoints Greg Martini as CFO

Tickers: $IRWD $KYTX

Topics: biotech CFO change executive appointment

Read the full article at Seeking Alpha

More World news

Nvidia CEO Jensen Huang Resigns Amid Personal Scandals and National Security Allegations CNBC · November 12, 2026, 13:51 UTC
Zenta Group Receives Nasdaq Notice Regarding Minimum Bid Price Requirement Seeking Alpha · November 12, 2026, 13:48 UTC
SoLo Funds Launches SoLo Alpha High-Yield Investment Account PR Newswire · November 12, 2026, 13:50 UTC
Artelo Biosciences Reports Third Quarter GAAP EPS of -$3.19 Seeking Alpha · November 12, 2026, 13:46 UTC
Monopar Therapeutics Reports Q3 GAAP EPS of -$0.72 in Line with Expectations Seeking Alpha · November 12, 2026, 13:48 UTC
Market Watch: Nvidia Pressure and Key Stocks NBIS, GOOG, GIS, and MANU Seeking Alpha · November 12, 2026, 13:48 UTC
Chevron Reports $10.4 Billion Third Quarter Profit Driven by High Refining Margins Motley Fool · November 12, 2026, 13:43 UTC
Replay Sports Cards Expands North Carolina Presence with New Greenville Location PR Newswire · November 12, 2026, 13:47 UTC
Linnworks Survey Reveals US E-commerce Businesses Limit AI Role to Operational Support Over Financial Control PR Newswire · November 12, 2026, 13:43 UTC
DocsInk Rebrands as TraceWell Health and Launches Integrated Care Platform PR Newswire · November 12, 2026, 13:44 UTC